Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baur, A. S.
Right arrow Articles by Chaubert, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baur, A. S.
Right arrow Articles by Chaubert, P.
Related Collections
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 94 No. 5 (September 1), 1999: pp. 1773-1781

Frequent Methylation Silencing of p15INK4b (MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas

By Audrey S. Baur, Phil Shaw, Nathalie Burri, Françoise Delacrétaz, Fred T. Bosman, and Pascal Chaubert

From Institut Universitaire de Pathologie, Lausanne, Switzerland.


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The methylation status of p15INK4b (MTS2), p16INK4a (MTS1) and p14ARF (p16beta ) was analyzed in 56 lymphomas by restriction-enzyme related polymerase chain reaction (PCR) (REP), methylation-specific PCR (MSP), and bisulfite genomic sequencing (BGS). Methylation of the p15 and p16 genes was detected, respectively, in 64% and 32% of the B-cell lymphomas, in 44% and 22% of the T-cell lymphomas, and in none of the 5 reactive lymph nodes analyzed. Both p15 and p16 genes were methylated more often in the high-grade (78% and 50%, respectively) than in the low-grade B-cell lymphomas (55% and 21%, respectively). For 5 cases, mapping of the methylated CpGs of the p16 promoter region confirmed the results of REP and MSP. In addition, a large variation in the methylation patterns of p16 exon 1 was observed, not only from one lymphoma to another, but also within a given tumor. Methylation of p15 and p16 was associated with an absence of gene expression, as assessed by reverse transcription-PCR. The p14 gene was unmethylated and normally expressed in all 56 tumors. We found no mutations of p15, p16, or p14 in any of the 56 lymphomas. Our results suggest a role for p15 and p16 gene methylation during lymphomagenesis and a possible association between p15 and p16 inactivation and aggressive transformation in B-cell and T-cell lymphomas.
© 1999 by The American Society of Hematology.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

UNCONTROLLED PROLIFERATION of tumor cells in lymphoma, as in other malignancies, is thought to result from a deregulation of 2 main pathways of cell-cycle control: the p53/p21 and p16/Rb pathways. Wild-type p53 induces transcription of the cyclin-dependent kinase (CDK) inhibitor p21WAF1.1 The lack of functional p53 protein, due to mutation or deletion of the gene, results in reduced p21 protein levels, preventing the association of p21 with cyclin-CDK complexes, which leads to cell-cycle activation. The Mdm2 protein can bind to and inactivate the transcriptional activity of p53, abrogating its antiproliferative effect.2 In addition, Mdm2 targets the p53 protein for rapid degradation.3 Therefore, Mdm2 overexpression may have the same biological consequences that p53 mutations have on cell proliferation.4,5 Mdm2, p53, and p21 gene alterations are relatively rare in hematological malignancies,6-13 suggesting that deregulation of the p53/p21 pathway does not play a central role in the genesis of these tumors.

Phosphorylation of pRb by cyclin D-CDK 4/6 complexes or Rb gene mutations lead to dissociation of the Rb-E2F complex and subsequent entry of the cell into the S phase. The p16INK4a (MTS1) tumor suppressor gene product14,15 acts as a negative regulator of cellular proliferation by interacting with CDK4 and inhibiting its kinase activity.16 In the absence of functional p16 protein, CDK4 binds to cyclin D and phosphorylates pRb, which stimulates entry into the S phase. The p16 gene is inactivated by mutations, homozygous deletions, or gene methylation in many tumors of diverse origin.17-19 The p16 locus encodes a second protein, referred to as p14ARF, p19ARF (mice), ORF2, or p16beta , resulting from a distinct exon 1 (exon 1beta ) spliced to the second shared exon of p16.20-22

The overexpression of p14 protein induces cell-cycle arrest in mammalian fibroblasts.20 The recently characterized p14 promoter23 is located within a CpG island and has been found methylated in several colon cancer cell lines. p16 and p14 (p19ARF) null mice develop diverse types of cancer including, notably, lymphomas.15,24 Recently, it has been shown that p14 promotes the rapid degradation of Mdm2, leading to stabilization and accumulation of p53.5,25 Thus, p14 gene inactivation might be one way to deregulate cell-cycle control through disruption of the p53/p21 pathway.

Another mechanism deregulating the cell cycle in neoplasia involves the p15INK4b (MTS2) gene. p15 displays high homology to p16, maps to the same region of chromosome 9, acts as inhibitor of CDK4 and 6,26 and has been proposed to have a tumor suppressor role.27 It is transcriptionally activated by transforming growth factor-beta (TGF-beta ). Homozygous deletions of the p15/p16 locus are found in a high proportion of acute lymphoblastic leukemias,6-7,28-35 adult T-cell leukemias,36,37 and chronic myeloid leukemias.38 Only a few studies have analyzed p15 and p16 gene alterations in lymphomas. Homozygous deletions involving p15 and/or p16 are found in a low proportion (0% to 19%) of B-cell lymphomas,39-45 where they seem to be associated with progression toward high-grade lesions.46,47 Hemizygous allele loss (loss of heterozygosity) of these 2 genes is somewhat more frequent than complete loss,46,48 but mutations are rarely observed.29,39,41-43,47,48 Methylation of p15 and/or p16 has been reported in several types of lymphomas,45 particularly in mucosa-associated lymphoid tissue (MALT) lymphomas, multiple myelomas, mantle cell lymphomas, Burkitt's lymphomas, and anaplastic large cell lymphomas.49-54

In the present work, we studied p15, p16, and p14 methylation status in human lymphomas to verify the role of methylation as a gene-silencing mechanism involved in lymphomagenesis. We specifically investigated the association of gene methylation with tumor grade and analyzed intra- and inter-tumor variations in the patterns of methylation.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Histopathological analysis.   Biopsy material from 56 non-Hodgkin's lymphomas (NHLs), as well as 5 nonspecific reactive lymphadenopathies from the files of the Department of Pathology of the University Hospital of Lausanne (Switzerland), was studied. Snap-frozen tissue was available for DNA extraction of all cases.

Morphological and immunophenotypical analysis was performed on formalin-fixed paraffin-embedded material. The cases were classified according to the Revised European American Lymphoma (REAL) classification55 and to the updated Kiel classification for NHLs.56 The series comprised of 47 B-cell lymphomas (BCL) and 9 T-cell lymphomas (TCL). The BCL included 8 chronic lymphocytic leukemia/small lymphocytic lymphomas, 6 mantle cell lymphomas, 1 splenic marginal zone lymphoma with villous lymphocytes, 14 follicle center cell lymphomas, 13 diffuse large B-cell lymphomas (9 centroblastic, 2 immunoblastic, 2 primary mediastinal), 1 T-cell rich BCL, 2 high-grade B-cell Burkitt-like lymphomas, and 2 Burkitt's lymphomas. According to the updated Kiel classification, 29 BCL were low grade and 18 were high grade. The TCL included 7 peripheral TCL (PTCL) and 2 anaplastic large cell lymphomas (ALCL).

For the assessment of methylation status and mRNA expression of p15, p16, and p14, snap-frozen tissue was used. Hematoxylin and eosin (H&E) sections of the frozen specimens used for DNA and RNA extraction were examined to ascertain representativity.

Methylation analysis of p15, p16, and p14.   The methylation status of p15, p16, and p14 exon 1 was determined by restriction enzyme-related polymerase chain reaction (PCR) (REP), as previously described.57 Genomic DNA samples were individually digested with 4 methyl-sensitive (Kspl, Hpall, Nael, and Eagl) and with 1 non-methyl-sensitive (Mspl) restriction enzyme, extracted with chloroform/phenol, and precipitated with ethanol before PCR. Undigested DNA was included as a positive control. A 150-bp fragment of p16 exon 1 containing 2 Hpall and 1 Kspl site, a 316-bp fragment of p14 exon 1 containing 1 Hpall and 1 Kspl site, and a 384-bp fragment of p15 exon 1 containing 1 Kspl, 1 Nael, 1 Eagl, and 5 Hpall sites were amplified by PCR. The primer sets and annealing temperatures used for PCR are given in Table 1 (H through J). Cases were considered positive for p15, p16, or p14 methylation by REP when PCR amplification was obtained after digestion with 1 of the methyl-sensitive restriction enzymes used. By REP, 3 CpG dinucleotides from p16 exon 1, 10 from p15 exon 1, and 2 from p14 exon 1 were evaluated.

                              
View this table:
[in this window]
[in a new window]
  		Table 1. Primers Used for PCR-SSCP, REP, MSP, BGS, and RT-PCR Analyses

In addition to REP, 2 other approaches were used to analyze the methylation status of p16 exon 1: methylation-specific PCR (MSP)58 and bisulfite genomic sequencing (BGS).59 In both techniques, DNA is chemically modified by sodium bisulfite, which changes the unmethylated but not the methylated cytosines into uracil. In MSP, the bisulfite-treated DNA is subjected to PCR amplification using primers designed to anneal specifically to the methylated bisulfite-modified DNA within a given gene. Thus, a PCR product is obtained when the sequence covered by the primers is methylated. MSP was performed as described by Herman et al,58 with some modifications. Briefly, genomic DNA (0.5 µg) was denatured in 0.3 mol/L NaOH (volume, 20 µL) for 20 minutes at 42°C. After the addition of 80 µL of a freshly prepared solution containing 1 mmol/L hydroquinone and 3.8 mol/L sodium bisulfite (pH 5.0), the samples were incubated overnight (16 hours) at 55°C. The bisulfite-treated DNA was purified on Wizard DNA Clean-Up columns (Promega, Madison, WI) according to the manufacturer's specifications and eluted with 50 µL of water. The DNA was treated with 0.3 mol/L NaOH for 20 minutes at 37°C, precipitated by ethanol, and resuspended in 20 µL of water. Bisulfite-modified DNA was amplified by PCR using 2 primer sets specific for methylated and 2 primer sets specific for unmethylated p16 sequence (Table 1, K through N), as described.58 Because tumor cells are always admixed with reactive cells in uncultured lymphomas, the PCR amplifications using primers specific for unmethylated DNA were considered as positive controls. Eleven CpG dinucleotides from p16 exon 1 were covered by MSP analysis.

In BGS, bisulfite-treated DNA is amplified by PCR using primers designed to recognize either methylated, or both methylated and unmethylated, bisulfite-modified sequences, then cloned and sequenced. This enables a precise mapping of the methylated CpG dinucleotides present in a given DNA fragment. First, we cloned the 234-bp PCR products obtained by MSP, either with primers specific for the methylated, or with those specific for the unmethylated, p16 exon 1 sequence (Table 1, L and N). This fragment contains 28 CpG dinucleotides. In some cases, we also cloned a 483-bp PCR fragment of the bisulfite-modified p16 promoter region obtained with primers recognizing both the methylated and the unmethylated p16 exon 1 sequence (Table 1, O). This fragment contains 42 CpG dinucleotides. Cloning of PCR products was performed using the pGEM-T vector system (Promega) according to the manufacturer's recommendations. Five to 10 clones from each PCR product were sequenced on an ALF Automatic DNA Analysis System (Amersham Pharmacia Biotech, Uppsala, Sweden).

Mutation analysis by PCR-single-stranded conformation polymorphism (SSCP).   The 3 exons of the p16 gene and the first exon of p15 and p14 were screened for mutations by PCR-SSCP as described previously.60 The primers and annealing conditions used for PCR amplification are given in Table 1 (A through G).

Reverse transcription (RT)-PCR analysis of p15, p16, and p14 mRNA expression.   Representative tissue from 16 lymphomas (15 BCL and 1 ALCL) and 2 reactive lymph nodes was suitable for mRNA analysis. In all 16 tumors, the proportion of neoplastic cells in the analyzed sample was more than 80%. Total RNA was extracted from tissue sections using the method of Chomczynski and Sacchi.61 Five hundred nanograms of total RNA was reverse transcribed using Moloney-murine leukemia virus (M-MLV) RT (Promega) and oligo dT primer (2.5 µmol/L) in 75 mmol/L KCl, 3 mmol/L MgCl2, 10 mmol/L dithiothreitol, 50 mmol/L Tris/HCl, pH 8.3, containing 1 mmol/L each dNTP and 0.5 U/µL RNasin (Promega). A 210-bp fragment from exon 1 to exon 2 of p16, a 207-bp fragment from exon 1 to exon 2 of p14, and a 182-bp fragment from exon 1 to exon 2 of p15 cDNA were amplified by PCR using the primer sets and annealing conditions indicated in Table 1 (R through T). In parallel, a 238-bp fragment at the 3' end of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH ) gene cDNA was amplified as a positive control (Table 1, U). Twenty-five cycles were performed for cDNA amplification, and the PCR product was analyzed on a 2% agarose gel. Under these conditions, and provided that their proportion was under 20%, p16 and p14 mRNA expression from reactive cells contaminating the tumor was not detectable (data not shown). Thus, absence of visible RT-PCR product for p15, p16, or p14 (with strongly positive GAPDH control) was considered to indicate absence of expression of these genes.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Methylation of the p15, p16, and p14 genes was analyzed in 56 lymphomas and 5 reactive lymph nodes by 3 different technologies: REP, MSP, and BGS (see Materials and Methods). In addition, the p15, p16, and p14 genes were analyzed by PCR-SSCP for mutation, and their mRNA expression was assessed by RT-PCR. The results are displayed in Table 2.

                              
View this table:
[in this window]
[in a new window]
  		Table 2. p15, p14, and p16 Gene Methylation, Mutation, and Expression in 56 BCL and TCL

Methylation status of the p15, p16, and p14 genes and correlation with lymphoma type.   Methylation of the p16 gene was found in 17 of 56 (30%) lymphomas: 15 of 47 (32%) BCL and 2 of 9 (22%) TCL. Of the BCL, 6 of 29 (21%) low-grade and 9 of 18 (50%) high-grade (Kiel classification) showed p16 methylation. The incidence of p16 gene methylation was higher in B-follicle center cell lymphomas (5 of 14) than in other low-grade lymphomas (1 of 15). Of the high-grade BCL, 6 of 13 diffuse large BCL (2 of 2 immunoblastic, 4 of 9 centroblastic, 0 of 2 mediastinal), 1 of 1 T-cell-rich BCL, 1 of 2 Burkitt-like, and 1 of 2 Burkitt's lymphomas were p16 methylated. The only PTCL showing p16 gene methylation corresponded to a pleomorphic T-cell lymphoma, predominantly large cell, high-grade (Kiel classification). One ALCL was shown to have a methylated p16 gene (Table 3).

                              
View this table:
[in this window]
[in a new window]
  		Table 3. Incidence of p15 and p16 Gene Methylation in BCL and TCL According to the Histopathological Subtypes

All the 17 lymphomas with a methylated p16 gene also had a methylated p15 gene. Overall, methylation of the p15 gene was found in 34 of 56 (61%) lymphomas: 30 of 47 (64%) BCL and 4 of 9 (44%) TCL. Of the BCL, 16 of 29 (55%) low grade and 14 of 18 (78%) high grade (Kiel classification) showed p15 gene methylation: 3 of 8 lymphocytic, 3 of 6 mantle cell, 1 of 1 marginal zone, 9 of 14 follicle center cell, 10 of 13 diffuse large B-cell (2 of 2 immunoblastic, 7 of 9 centroblastic, 1 of 2 mediastinal), 1 of 1 T-cell rich, 2 of 2 Burkitt-like, and 1 of 2 Burkitt's lymphomas. Two of the 7 PTCL were positive for p15 gene methylation; both were large cell lymphomas, high grade (Kiel classification). Both ALCL exhibited methylation of the p15 gene (Table 3).

There was no detectable methylation of the p14 gene in any of the 56 lymphomas. In all 5 reactive lymph nodes, the p15, p16, and p14 genes were unmethylated. The results of three cases are illustrated in Fig 1.


View larger version (41K):
[in this window]
[in a new window]
  		Fig 1. Analysis of p16, p15, and p14 gene methylation and mRNA expression in 3 diffuse large BCL. The methyl-sensitive restriction enzymes used for REP are indicated (HpaII, KspI, NaeI, and EagI); digestion with the non-methyl-sensitive enzyme MspI serves as a negative control; undigested DNA (Control) serves as a positive control. For MSP, 2 primer sets specific for the methylated (M1 and M2) and 2 for the unmethylated (U1 and U2) bisulfite-modified p16 gene are used. Expression of p16, p15, and p14 mRNA is analyzed by RT-PCR. The p16 gene is methylated in cases 33 and 36 but unmethylated in case 30. In case 36, p16 methylation is detected by REP but not by MSP (A and B). The p15 gene is methylated in cases 33 and 36 but not in case 30. In case 33, all assessed restriction sites are methylated. In case 36, all sites except EagI are methylated (C). The p14 gene is unmethylated in all 3 cases (D). GAPDH and p14 mRNA is present in all cases; p15 mRNA is detectable in case 30 but not in cases 33 and 36, whereas p16 mRNA is present in cases 30 and 36 but not in case 33 (E).

Methylation patterns of p16 exon 1.   Of the 56 lymphomas analyzed for p16 gene methylation by REP and MSP, 17 were methylated. In 12 cases, methylation was shown by both methods (REP+/MSP+). In the 5 other cases, it was detected only by REP, but not by MSP (REP+/MSP-), indicating partial methylation in p16 exon 1 (Fig 1). To document this, 5 lymphomas (3 REP+/MSP+ and 2 REP+/MSP-) were analyzed by BGS, which enables a precise mapping of the methylated CpGs in the analyzed DNA fragment.

We first cloned and sequenced PCR products obtained by MSP with primers specific for either the methylated (REP+/MSP+ cases), or the unmethylated (REP+/MSP- cases) bisulfite-modified p16 exon 1 sequence. In both REP+/MSP- cases, we also cloned and sequenced a PCR product obtained with primers recognizing both methylated and unmethylated sequences. In the 3 REP+/MSP+ lymphomas, the different p16 exon 1 methylation patterns exhibited methylation at all or almost all of the CpG dinucleotides (Table 4, clones 33.a through 33.e, 42.a through 42.e, and 44.a through 44.e). In both REP+/MSP- lymphomas, all the sequenced clones were completely or almost completely unmethylated (Table 4, clones 36.a through 36.m and 47.a through 47.o); of the 11 CpG sites covered by MSP analysis, 8 were unmethylated in all clones, explaining the negative results obtained by MSP with the methylated primer sets.

                              
View this table:
[in this window]
[in a new window]
  		Table 4. Methylation Patterns of p16 Exon 1 Region Analyzed by BGS in Five Lymphomas

Expression of p15, p16, and p14 mRNA and correlation with methylation status.   Suitable tissue for mRNA extraction and RT-PCR analysis was available in 18 cases (16 lymphomas and 2 reactive lymph nodes). All tissues were strongly positive for GAPDH and p14 mRNA expression. The p16 mRNA was present in both reactive lymph nodes and in the 4 p16-unmethylated and 1 p16-methylated lymphomas. There was no detectable p16 mRNA expression in 11 of 12 lymphomas with a methylated p16 gene (Table 2).

p15 mRNA was detected in both reactive lymph nodes and in the 4 p15-unmethylated lymphomas, but not in any of the 12 lymphomas exhibiting p15 gene methylation (Table 2). p15, p16, and p14 mRNA expression in 3 lymphomas is illustrated in Fig 1.

Mutation analysis of the p15, p16, and p14 genes by PCR-SSCP.   All 56 lymphomas and 5 reactive lymph node tissues were screened by PCR-SSCP for mutations of p16 exon 1 to 3, p15 exon 1, and p14 exon 1. No aberrant migration patterns, indicative of mutation, were observed (Table 2).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Inactivation of p15INK4b and p16INK4a by homozygous deletion or gene methylation is probably one of the most common molecular events in hematological malignancies.52 Homozygous deletion of the 9p21 region containing the p15, p16, and p14 genes is frequently found in acute lymphoblastic leukemias of both B-cell and T-cell lineage, but is uncommon in lymphomas. In agreement with other studies,29,34,41,54 we did not find any mutations in the coding regions of the p15 and p16 genes among the 56 lymphomas analyzed. Thus, neither homozygous deletion nor mutation appears to be a relevant mode of inactivation of these genes during lymphomagenesis.29,39,41,45,54 Our results indicate that the principal mechanism of p15 and p16 silencing in lymphomas is gene methylation.45 A large proportion of lymphomas showed p15 and/or p16 gene methylation (61% and 30%, respectively), confirming previously reported results.49,50,52-54 Both genes were inactivated more frequently in BCL than in TCL, suggesting that they are more important in B than in T lymphomagenesis. High-grade (according to the Kiel classification) BCL were more often p15/p16 methylated (78% and 50%, respectively) than low-grade B-cell lymphomas (55% and 21%, respectively). This suggests that p15 and p16 gene silencing might be associated with aggressive transformation in lymphoma, and that p15 and p16 gene methylation might be a useful marker to predict aggressive behavior.

Both p16 and p14 (p19ARF) null mice develop lymphomas.15,24 However, given the fact that the p14 gene was also disrupted in the p16 null mice, it has been proposed that the major oncogenic event might be loss of p14 rather than of p16.24 We observed absence of p14 gene mutations or methylation and a high level of p14 mRNA expression in all lymphomas analyzed, which does not suggest a role for p14 inactivation in human lymphomagenesis. Our results indicate that one of the principal oncogenic events in human lymphomagenesis is inactivation of the p15 gene. Therefore, it could be of interest to determine whether p15 knockout mice develop lymphomas. In our series, all lymphomas with a methylated p16 gene were also p15 methylated. It is striking that p14, a gene that is localized between p15 and p16, was always unmethylated even when both p15 and p16 genes were methylated. A possible mechanism protecting p14 from de novo methylation might be binding of the Sp1 transcription factor at Sp1 sites present in the p14 promoter, as proposed recently.23

The minimal sequence required by the methylation apparatus is a CpG dinucleotide.62 The present results are the first demonstrating variation in methylated CpGs within p16 exon 1 from one lymphoma to another. Three cases positive by MSP and REP displayed a high proportion of methylated and a few scattered unmethylated CpG dinucleotides by BGS. In contrast, 2 cases positive by REP but negative by MSP had only a few scattered methylated CpGs within p16 exon 1. The significance of such heterogeneity of methylation patterns remains unclear, but suggests a complex mechanism for de novo methylation. Even those tumors with a few methylated CpGs within p16 exon 1 had no detectable p16 mRNA expression, indicating that low-level methylation is sufficient to repress p16 transcription. Recently, it has been shown that methyl-CpG-binding protein 2 (MeCP2), which is involved in transcriptional repression of methylated genes by forming complexes with the transcriptional repressor Sin3A and histone deacetylase (HD), may bind to DNA sequences containing only a single methylated CpG dinucleotide.63,64 However, it remains to be shown that transcriptional repression of methylated p15 and p16 involves the MeCP2/Sin3A/HD-complex/pathway. By BGS, we found several p16 methylation patterns coexisting in DNA extracted from a primary (uncultured) lymphoma, an observation for which several explanations might be considered. First, consecutive waves of clonal progression might yield heterogeneous p16 methylation patterns coinciding with different tumor regions. This could be confirmed by methylation analysis of microdissected tumor samples. Secondly, the 2 (or more) p16 alleles in a single tumor cell might have different methylation patterns. The latter possibility is supported by observations that several methylation patterns of p16 exon 1 coexist in established colon cancer cell lines (P.C., unpublished data).


    ACKNOWLEDGMENT

The authors acknowledge M.M. Bertholet, M. Correvon, S. Burki, and J. Maillardet for technical assistance.


    FOOTNOTES

Submitted January 19, 1999; accepted May 4, 1999.

Supported by the Swiss Cancer League (P.C.)

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

Address reprint requests to Pascal Chaubert, MD, Institut Universitaire de Pathologie, Bugnon 25, CH-1011 Lausanne, Switzerland.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993[Medline] [Order article via Infotrieve]

2. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237, 1992[Medline] [Order article via Infotrieve]

3. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387:296, 1997[Medline] [Order article via Infotrieve]

4. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80, 1992[Medline] [Order article via Infotrieve]

5. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725, 1998[Medline] [Order article via Infotrieve]

6. Hebert J, Cayuela JM, Berkeley J, Sigaux F: Candidate tumor-suppressor genes MTS1 (p16 INK4A) and MTS2 (p15 INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038, 1994[Abstract/Free Full Text]

7. Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa S, Kamada N, Kobayashi Y, Takemoto Y, Kitani T, Toyama K, Ohtake S, Yazaki Y, Ueda R, Hirai H: Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 87:4949, 1996[Abstract/Free Full Text]

8. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V, Laurino L, Carbone A, Boiocchi M: MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 85:3239, 1995[Abstract/Free Full Text]

9. Watanabe T, Ichikawa A, Saito H, Hotta T: Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymph 21:391, 1996[Medline] [Order article via Infotrieve]

10. Kawamata N, Miller C, Levy V, Shintaku IP, Koeffler HP, Said JW: mdm-2 oncogene expression in non-Hodgkin's lymphomas. Diagn Mol Pathol 5:33, 1996[Medline] [Order article via Infotrieve]

11. Villuendas R, Pezzella F, Gatter K, Algara P, Sanchez-Beato M, Martinez P, Martinez JC, Munoz K, Garcia P, Sanchez L, Kocialkowsky S, Campo E, Orradre JL, Piris MA: p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MSM2-, p21-immunophenotype associated with missence p53 mutations. J Pathol 181:51, 1997[Medline] [Order article via Infotrieve]

12. Capoulade C, Bressac de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T, Wiels J: Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16:1603, 1998[Medline] [Order article via Infotrieve]

13. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF, Piris MA: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16:1931, 1998[Abstract]

14. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704, 1993[Medline] [Order article via Infotrieve]

15. Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D, Depinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27, 1996[Medline] [Order article via Infotrieve]

16. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545, 1995[Abstract]

17. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686, 1995[Medline] [Order article via Infotrieve]

18. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531, 1995[Abstract/Free Full Text]

19. Herman JG, Merlo A, Mao LI, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525, 1995[Abstract/Free Full Text]

20. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993, 1995[Medline] [Order article via Infotrieve]

21. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55:2988, 1995[Abstract/Free Full Text]

22. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 55:2995, 1995[Abstract/Free Full Text]

23. Robertson KD, Jones PA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18:6457, 1998[Abstract/Free Full Text]

24. Kamijo T, Zindy F, Roussel MF, Quelle DE, Sowning JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649, 1997[Medline] [Order article via Infotrieve]

25. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713, 1998[Medline] [Order article via Infotrieve]

26. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta -induced cell cycle arrest. Nature 371:257, 1994[Medline] [Order article via Infotrieve]

27. Herman JG, Jen J, Merlo A, Baylin SB: Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B1. Cancer Res 56:722, 1996[Abstract/Free Full Text]

28. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, Pelicci PG, Lo Coco F: Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85:2685, 1995[Abstract/Free Full Text]

29. Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M: Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436, 1995[Abstract/Free Full Text]

30. Heymann M, Einhorn S: Inactivation of the p15INK4B and p16INK4 genes in hematologic malignancies. Leuk Lymph 23:235, 1996[Medline] [Order article via Infotrieve]

31. Siebert R, Willers CP, Schramm A, Fossa A, Gana Dresen IM, Uppenkamp M, Nowrousian MR, Seeber S, Opalka B: Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukemia cell lines. Br J Haematol 91:350, 1995[Medline] [Order article via Infotrieve]

32. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893, 1995[Abstract/Free Full Text]

33. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI: Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 86:1931, 1995[Abstract/Free Full Text]

34. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H: Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86:1548, 1995[Abstract/Free Full Text]

35. Siebert R, Willers CP, Opalka B: Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Leuk Lymph 23:505, 1996[Medline] [Order article via Infotrieve]

36. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP: Homozygous deletions of the p15(MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 85:2699, 1995[Abstract/Free Full Text]

37. Yamada Y, Hatta Y, Murata K, Sugawara K, Ikeda S, Mine M, Maeda T, Hirakata Y, Kamihira S, Tsukasaki K, Ogawa S, Hirai H, Koeffler HP, Tomonaga M: Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 15:1778, 1997[Abstract/Free Full Text]

38. Sill H, Goldman JM, Cross NCP: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013, 1995[Abstract/Free Full Text]

39. Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T: Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood 86:2724, 1995[Abstract/Free Full Text]

40. Neumeister P, Hoefler G, Beham-Schmid C, Schmidt H, Apfelbeck U, Schaider H, Linkesch W, Sill H: Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology 112:1871, 1997[Medline] [Order article via Infotrieve]

41. Koduru PRK, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD: Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood 86:2900, 1995[Abstract/Free Full Text]

42. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP: Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood 86:1434, 1995

43. Tasaka T, Berenson J, Vescio R, Hirama T, Miller CW, Nagai M, Takahara J, Koeffler HP: Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. Br J Haematol 96:98, 1997[Medline] [Order article via Infotrieve]

44. Dreyling MH, Bulliger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, Hiddemann W, Döhner H: Alterations of the cyclin D1/p16-pRb pathway in mantle cell lymphoma. Cancer Res 57:4608, 1997[Abstract/Free Full Text]

45. Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845, 1998[Medline] [Order article via Infotrieve]

46. Elenitoba-Johnson KSJ, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M: Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677, 1998[Abstract/Free Full Text]

47. Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL, Montserrat E, Cardesa A, Lopez-Otin C, Campo E: Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272, 1997[Abstract/Free Full Text]

48. Fernandez-Piqueras J, Santos J, Pérez de Castro I, Meléndez B, Martinez B, Robledo M, Rivas C, Benitez J: Frequent allelic losses of 9p21 markers and low indidence of mutations at p16(CDKN2) gene in non-Hodgkin's lymphomas of B-cell lineage. Cancer Genet Cytogenet 98:63, 1997[Medline] [Order article via Infotrieve]

49. Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J: Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 11:425, 1997[Medline] [Order article via Infotrieve]

50. Martinez-Delgado B, Robledo M, Arranz E, Osorio A, Garcia MJ, Echezarreta G, Rivas C, Benitez J: Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 12:937, 1998[Medline] [Order article via Infotrieve]

51. Tasaka T, Asou H, Munker R, Said JW, Berenson J, Vescio RA, Nagai M, Takahara J, Koeffler HP: Methylation of the p16INK4A gene in multiple myeloma. Br J Haematol 101:558, 1998[Medline] [Order article via Infotrieve]

52. Herman JG, Civin CI, Issa JPJ, Collector MI, Sharkis SJ, Baylin SB: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837, 1997[Abstract/Free Full Text]

53. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG: p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91:1680, 1998[Abstract/Free Full Text]

54. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89:2500, 1997[Abstract/Free Full Text]

55. Harris NL, Jaffe ES, Sein H, Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peteers C, Falini B, Gatter K, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri S, Piris MA, Ralfkiaer E, Warnke R: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994[Free Full Text]

56. Stansfeld AG, Diebold J, Kapanci Y, Noël H, Rilke F, Kelenyi G, Sundstrom C, Lennert K, Van-Unnik JAM, Mioduszewska O, Wright DH: Updated Kiel classification of non-Hodgkin's lymphoma. Lancet 1:292, 1988[Medline] [Order article via Infotrieve]

57. Chaubert P, Guillou L, Kurt AM, Bertholet MM, Metthez G, Leisinger HJ, Bosman F, Shaw P: Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol 151:859, 1997[Abstract]

58. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821, 1996[Abstract/Free Full Text]

59. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827, 1992[Abstract/Free Full Text]

60. Chaubert P, Bautista D, Benhattar J: An improved method for rapid screening of DNA mutations by nonradioactive single-strand conformation polymorphism procedure. BioTechniques 15:586, 1993[Medline] [Order article via Infotrieve]

61. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987[Medline] [Order article via Infotrieve]

62. Bird A: The essentials of DNA methylation (review). Cell 70:5, 1992[Medline] [Order article via Infotrieve]

63. Nan X, Campoy J, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88:471, 1997[Medline] [Order article via Infotrieve]

64. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386, 1988

© 1999 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea